Activity of trioxaquine PA1259 in mice infected by Schistosoma mansoni

Schistosomiasis is a chronic life-threatening parasitic disease concerning more than 200 million people in the World. Little attention has been paid to schistosomiasis over the last 30 years, and praziquantel is the only drug in use to control this disease. In the absence of a vaccine, there is a real need for new drugs in order both to improve the efficacy of the treatment and to delay the development of praziquantel resistant schistosomes. The present note reports the significant reduction of the worm burden after oral administration of trioxaquine PA1259 to mice infected by Schistosoma mansoni. (C) 2011 Academie des sciences. Published by Elsevier Masson SAS. All rights reserved.